What Are GLP-1 Medications?
GLP-1 receptor agonists are a class of prescription medications originally developed for type 2 diabetes. They mimic a natural hormone called glucagon-like peptide-1, which your gut produces after eating. Medications like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (used in Mounjaro and Zepbound) have shown remarkable results for weight management in clinical trials, leading to FDA approval specifically for weight loss.
How They Reduce Appetite
GLP-1 medications work primarily by targeting receptors in the brain that regulate hunger and satiety. When you take these medications, they slow gastric emptying — meaning food stays in your stomach longer — and signal to your brain that you are full. Many patients describe it as the volume being turned down on food noise: the constant background chatter of cravings and hunger that can make weight management so difficult. This isn't willpower — it's biochemistry.
The Role of Insulin and Blood Sugar
Beyond appetite suppression, GLP-1 medications help regulate blood sugar by stimulating insulin release when glucose levels are high and reducing glucagon secretion. This dual action helps prevent the blood sugar spikes and crashes that often trigger cravings and overeating. For patients with insulin resistance — a common factor in weight gain — this mechanism can be particularly beneficial.
Tirzepatide: The Dual-Action Approach
Tirzepatide takes things a step further by targeting two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-agonist approach has shown even greater weight loss results in clinical trials, with some participants losing over 20% of their body weight. The GIP receptor activation provides additional metabolic benefits that complement the GLP-1 pathway.
What to Realistically Expect
Clinical trials show average weight loss of 15-20% of body weight with semaglutide and up to 22% with tirzepatide over 68–72 weeks. However, results vary significantly between individuals. Most patients begin noticing appetite changes within the first two weeks, with meaningful weight loss becoming visible around weeks 4-8. The medications are typically administered as once-weekly injections, with doses gradually increased over several months to minimize side effects.
Common Side Effects
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are usually most pronounced during dose increases and tend to improve over time. Starting at a low dose and gradually titrating up helps most patients manage these effects. More serious but rare side effects include pancreatitis and gallbladder problems, which is why medical supervision during treatment is important.
